Stockscreener 앱 받기
2.05
1.49%
0.03
시간 외 거래:
2.04
-0.010
-0.49%
전일 마감가:
$2.02
열려 있는:
$2.04
하루 거래량:
2.84M
Relative Volume:
0.62
시가총액:
$174.60M
수익:
-
순이익/손실:
$-59.69M
주가수익비율:
-1.4748
EPS:
-1.39
순현금흐름:
$-46.54M
1주 성능:
+4.59%
1개월 성능:
-23.51%
6개월 성능:
+5.67%
1년 성능:
-6.39%
1일 변동 폭
$2.02
$2.10
1주일 범위
$1.9531
$2.10
52주 변동 폭
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
MIST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
2.05 | 172.04M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-09-11 | 개시 | Wells Fargo | Overweight |
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
MIST: HC Wainwright & Co. Reiterates Buy Rating with $8 Price Ta - GuruFocus
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright - MarketBeat
Milestone Pharmaceuticals Says EMA Accepts Marketing Application for Etripamil Nasal Spray - marketscreener.com
Milestone’s PSVT nasal spray MAA accepted by EMA - TipRanks
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency - The Manila Times
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire
Simplify Asset Management Inc. Boosts Stock Holdings in Milestone Pharmaceuticals Inc. $MIST - MarketBeat
Milestone Pharmaceuticals Inc. (MIST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Travel Stocks: How Milestone Pharmaceuticals Inc stock trades before earningsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - moha.gov.vn
Milestone Pharmaceuticals’ Stock Surges as Cardamyst Receives FDA Approval - StocksToTrade
Milestone Pharmaceuticals (MIST) price target increased by 76.00% to 6.73 - MSN
Wyckoff Accumulation Phase Possible in Aveer Foods LimitedVWAP Trading Strategies & Double Or Triple Profits - earlytimes.in
Milestone Pharmaceuticals (MIST) Price Target Increased by 76.00% to 6.73 - Nasdaq
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to "Hold" at Wall Street Zen - MarketBeat
Will Milestone Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Earnings & Fast Moving Stock Trade Plans - Улправда
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Can Milestone Pharmaceuticals Inc. stock deliver strong Q4 earningsChart Signals & Long-Term Growth Portfolio Plans - Улправда
Milestone Pharmaceuticals shares rally after FDA greenlights first at-home PSVT nasal therapy - MSN
Aug Intraday: Will Milestone Pharmaceuticals Inc. stock gain from lower inflationWeekly Market Outlook & Entry and Exit Point Strategies - Улправда
How supply chain issues affect Milestone Pharmaceuticals Inc. stock2025 Biggest Moves & Weekly Return Optimization Plans - DonanımHaber
Can Milestone Pharmaceuticals Inc. stock deliver consistent earnings growth2025 Trading Recap & Real-Time Stock Entry Alerts - Улправда
Best Penny Stocks To Watch TodayDecember 15th - MarketBeat
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Business Wire
What is HC Wainwright's Estimate for MIST FY2026 Earnings? - MarketBeat
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) – Company AnnouncementFT.com - Financial Times
Wells Fargo maintains Milestone Pharmaceuticals (MIST) overweight recommendation - MSN
Wells Fargo Maintains Milestone Pharmaceuticals (MIST) Overweight Recommendation - Nasdaq
Traders Purchase High Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Wells Fargo Raises Price Target for Milestone Pharmaceuticals (M - GuruFocus
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval - Yahoo Finance
Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray - Yahoo Finance
Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential - TipRanks
Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST) - Seeking Alpha
Milestone Embarks On ‘Show-Me’ Story With Cardamyst Launch - Citeline News & Insights
HC Wainwright & Co. Maintains Milestone Pharmaceuticals (MIST) Buy Recommendation - Nasdaq
Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval - Investing.com Canada
MIST Stock Upgraded to 'Buy' by TD Cowen with New Price Target | - GuruFocus
MIST: Analyst Raises Price Target by 60% Amid Positive Outlook | - GuruFocus
Milestone Pharmaceuticals (MIST) Stock Jumps 35% on Groundbreaking FDA Approval - parameter.io
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to Buy at TD Cowen - MarketBeat
Milestone’s long regulatory road ends in approval for Cardamyst - PharmaLive
Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT TreatmentSlideshow (NASDAQ:MIST) 2025-12-15 - Seeking Alpha
MIST stock soars pre-market after FDA approves first commercial product – retail remains bullish, dismisses 'sell the news' concerns - MSN
Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST - TipRanks
Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats - Sahm
Why Is Milestone Pharmaceuticals Stock Skyrocketing Monday?Milestone Pharmaceuticals (NASDAQ:MIST) - Benzinga
Milestone Pharmaceuticals (MIST) Stock: Wild Price Swings Follow FDA Approval Decision - Blockonomi
[8-K] Milestone Pharmaceuticals Inc. Reports Material Event | MIST SEC FilingForm 8-K - Stock Titan
Milestone’s Long Regulatory Road Ends in Approval for Cardamyst - BioSpace
MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns - Stocktwits
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):